What's Happening?
Niagen Bioscience, Inc. (NAGE) has released its third-quarter 2026 earnings, reporting net sales of $27.2 million, a 20% decrease from the prior year. Tru Niagen revenue, accounting for 86% of total net sales, declined by 10% year-over-year, though direct-to-consumer
website sales grew by 13%, or 17% when adjusted for Prime Day timing. The company experienced a net loss of $1.2 million, or $0.01 per diluted share, compared to a net income of $4.6 million in Q3 2025, attributed to higher operating expenses and lower sales. Adjusted EBITDA remained positive at $455,000, down from $6.4 million in the prior year. Niagen Bioscience ended the quarter with $69.5 million in cash and no debt, emphasizing 2026 as an investment year to prepare for growth in 2027. The company is expanding its NAD platform across consumer products, ingredients, skincare, and pharmaceuticals, and has initiated a large-scale clinical prevention trial with Mass General Brigham.
Why It's Important?
The financial results highlight the challenges faced by Niagen Bioscience in a competitive market, particularly from NMN products, which are impacting its ingredients business. Despite the revenue decline and net loss, the company's strategic investments in research and development, brand awareness campaigns, and new product launches are crucial for its long-term positioning in the healthy aging and longevity markets. The partnership with Mass General Brigham and Dr. Howard Sesso for a large-scale prevention trial is a significant step, aiming to further validate Niagen's efficacy and strengthen its scientific leadership. This study, similar to past longitudinal trials for major dietary supplement ingredients, could provide substantial evidence for Niagen's benefits in healthy aging, potentially influencing consumer trust and market share. The development of a new, more cost-efficient malate salt form of nicotinamide riboside and the advancement of the NB4168 drug candidate also signal future growth opportunities and potential for reduced production costs.
What's Next?
Niagen Bioscience anticipates an improvement in fourth-quarter revenue sequentially from the third quarter. The company plans to commercialize a new, more cost-efficient malate salt form of nicotinamide riboside in early 2027, which is expected to reduce costs of goods and strengthen its ingredients business. They also intend to integrate this new salt form into their Tru Niagen product portfolio eventually. In skincare, a topical product incorporating Niagen, developed in partnership with a major global skincare company, is expected to launch in early 2027, with a new branded skincare product following in the first half of 2027. The NB4168 drug candidate is advancing, with IND-enabling studies underway and first-in-human studies planned for 2027, subject to regulatory clearance. The company is also exploring potential joint ventures or separate financing arrangements for its NAD pharmaceuticals segment to maximize shareholder value.
Beyond the Headlines
The ongoing patent litigation against Elysium, where Niagen Bioscience recently received a favorable ruling regarding attorney's fees, underscores the legal complexities and intellectual property battles within the rapidly evolving NAD supplement market. The company's lawsuit against the FDA concerning its decision on NMN further highlights the regulatory challenges and the company's commitment to asserting its market position. The expansion into new distribution channels like Walmart.com, GNC, and Sam's Club, along with the 'Don't Get Old, Age Better' campaign featuring celebrity endorsements, reflects a broader strategy to increase brand awareness and consumer adoption. The focus on rare disease development for NB4168, supported by FDA initiatives for flexible trial designs and the potential for priority review vouchers, indicates a strategic pivot towards high-value pharmaceutical assets, which could significantly impact the company's long-term revenue and market valuation.
